- Home
- NRXP vs AARD Comparison
NRXP vs AARD Comparison
Compare NRXP & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NRXP | AARD |
|---|---|---|
| Founded | 2015 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 151.1M | 107.7M |
| IPO Year | 2017 | 2025 |
Fundamental Metrics
Financial Performance| Metric | NRXP | AARD |
|---|---|---|
| Price | $3.29 | $5.57 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $38.25 | $15.29 |
| AVG Volume (30 Days) | ★ 619.7K | 125.5K |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 69.70 | 43.11 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,225,000.00 | N/A |
| Revenue This Year | $2,547.84 | N/A |
| Revenue Next Year | $1,591.73 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.65 | $3.35 |
| 52 Week High | $5.06 | $17.94 |
Technical Indicators
Market Signals| Indicator | NRXP | AARD |
|---|---|---|
| Relative Strength Index (RSI) | 45.06 | 47.39 |
| Support Level | $3.09 | $5.47 |
| Resistance Level | $3.62 | $6.01 |
| Average True Range (ATR) | 0.14 | 0.55 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 43.82 | 59.53 |
Price Performance
Historical ComparisonAbout NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
About AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.